{"schema_version":"secwatch.filing_event.v1","accession":"0001759425-26-000044","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2026-08-05T20:02:41+00:00","discovered_at":"2026-08-05T20:04:00.219130+00:00","generated_at":"2026-08-05T20:04:44.554487+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Mirum Q2 net product sales $176M, raises FY guidance to $680-700M; volixibat NDA delayed to H1 2027","bullets":["Q2 2026 net product sales $176.2M, up 38% YoY; LIVMARLI sales $128.7M (+46% YoY), Bile Acid Medicines $47.5M (+20% YoY).","Full-year 2026 net product sales guidance raised to $680-700M from prior range.","Volixibat granted Breakthrough Therapy and Orphan Drug Designations for PSC; pre-NDA meeting recommended Phase 3 study, NDA submission now targeted H1 2027.","Issued $690M of 0.00% convertible senior notes due 2032; settled $237.2M of 4.00% notes due 2029.","Cash and investments $561.3M as of June 30, 2026; zilurgisertib PDUFA date Sept 26, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001759425-26-000044","json":"https://secwatch.observer/filing/0001759425-26-000044.json","markdown":"https://secwatch.observer/filing/0001759425-26-000044.md","text":"https://secwatch.observer/filing/0001759425-26-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/0001759425-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:04:44.554487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}